CALTX Stock Overview
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
Calliditas Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr112.10|
|52 Week High||kr139.60|
|52 Week Low||kr62.00|
|1 Month Change||18.69%|
|3 Month Change||51.38%|
|1 Year Change||3.41%|
|3 Year Change||107.98%|
|5 Year Change||n/a|
|Change since IPO||138.54%|
Recent News & Updates
Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|CALTX||SE Pharmaceuticals||SE Market|
Return vs Industry: CALTX exceeded the Swedish Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: CALTX exceeded the Swedish Market which returned -21.8% over the past year.
|CALTX Average Weekly Movement||9.1%|
|Pharmaceuticals Industry Average Movement||7.8%|
|Market Average Movement||7.2%|
|10% most volatile stocks in SE Market||12.6%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: CALTX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CALTX's weekly volatility (9%) has been stable over the past year.
About the Company
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company’s lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease.
Calliditas Therapeutics Fundamentals Summary
|CALTX fundamental statistics|
Is CALTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CALTX income statement (TTM)|
|Cost of Revenue||kr614.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 18, 2022
|Earnings per share (EPS)||-9.74|
|Net Profit Margin||-206.56%|
How did CALTX perform over the long term?See historical performance and comparison
Is CALTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CALTX?
Other financial metrics that can be useful for relative valuation.
|What is CALTX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CALTX's PS Ratio compare to its peers?
|CALTX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
KARO Karo Pharma
CALTX Calliditas Therapeutics
Price-To-Sales vs Peers: CALTX is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (8x).
Price to Earnings Ratio vs Industry
How does CALTX's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Sales vs Industry: CALTX is expensive based on its Price-To-Sales Ratio (23.8x) compared to the Swedish Pharmaceuticals industry average (15x)
Price to Sales Ratio vs Fair Ratio
What is CALTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||23.8x|
|Fair PS Ratio||66.2x|
Price-To-Sales vs Fair Ratio: CALTX is good value based on its Price-To-Sales Ratio (23.8x) compared to the estimated Fair Price-To-Sales Ratio (66.2x).
Share Price vs Fair Value
What is the Fair Price of CALTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CALTX (SEK112.1) is trading below our estimate of fair value (SEK6618.43)
Significantly Below Fair Value: CALTX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Calliditas Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CALTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: CALTX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CALTX is expected to become profitable in the next 3 years.
Revenue vs Market: CALTX's revenue (52.4% per year) is forecast to grow faster than the Swedish market (10.9% per year).
High Growth Revenue: CALTX's revenue (52.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CALTX's Return on Equity is forecast to be very high in 3 years time (83.7%).
Discover growth companies
How has Calliditas Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CALTX is currently unprofitable.
Growing Profit Margin: CALTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CALTX is unprofitable, and losses have increased over the past 5 years at a rate of 51.6% per year.
Accelerating Growth: Unable to compare CALTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CALTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
Return on Equity
High ROE: CALTX has a negative Return on Equity (-67.01%), as it is currently unprofitable.
Discover strong past performing companies
How is Calliditas Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CALTX's short term assets (SEK896.5M) exceed its short term liabilities (SEK167.1M).
Long Term Liabilities: CALTX's short term assets (SEK896.5M) exceed its long term liabilities (SEK306.1M).
Debt to Equity History and Analysis
Debt Level: CALTX has more cash than its total debt.
Reducing Debt: CALTX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CALTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CALTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Calliditas Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CALTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CALTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CALTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CALTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CALTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Renee Aguiar-Lucander (60 yo)
Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...
CEO Compensation Analysis
Compensation vs Market: Renee's total compensation ($USD1.04M) is above average for companies of similar size in the Swedish market ($USD796.68K).
Compensation vs Earnings: Renee's compensation has increased whilst the company is unprofitable.
Experienced Management: CALTX's management team is considered experienced (2.6 years average tenure).
Experienced Board: CALTX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.
Calliditas Therapeutics AB (publ)'s employee growth, exchange listings and data sources
- Name: Calliditas Therapeutics AB (publ)
- Ticker: CALTX
- Exchange: OM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr6.632b
- Shares outstanding: 59.16m
- Website: https://www.calliditas.se
Number of Employees
- Calliditas Therapeutics AB (publ)
- Kungsbron 1, D5
- Stockholm County
- 111 22
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.